Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
Anita KumarCarla CasuloRanjana H AdvaniElizabeth BuddePaul M BarrConnie Lee BatleviPhilip CaronLouis S ConstineSavita V DandapaniEsther DrillPamela DrullinskyJonathan W FriedbergClare GrieveAudrey HamiltonPaul A HamlinRichard T HoppeSteven M HorwitzAshlee JosephNiloufer KhanLeana LaraqueMatthew J MatasarAlison J MoskowitzAriela NoyMaria Lia PalombaHeiko SchöderDavid J StrausShreya VemuriJoanna YangAnas YounesAndrew D ZelenetzJoachim YahalomCraig H MoskowitzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
BV + AVD × four cycles is a highly active and well-tolerated treatment program for ES, unfavorable-risk Hodgkin lymphoma, including bulky disease. The efficacy of BV + AVD supports the safe reduction or elimination of consolidative radiation among PET-4-negative patients.
Keyphrases
- hodgkin lymphoma
- newly diagnosed
- early stage
- end stage renal disease
- lipopolysaccharide induced
- lps induced
- ejection fraction
- chronic kidney disease
- computed tomography
- squamous cell carcinoma
- peritoneal dialysis
- locally advanced
- prognostic factors
- quality improvement
- pet ct
- inflammatory response
- sentinel lymph node
- combination therapy
- rectal cancer
- lymph node